Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stott

Showing results (61-70 of 87) with videos related to

Pageof 9
Sort By:
Clinical and Experimental Immunology|April 26, 2006
The analysis and quantification of a clonal B cell response in a hyperimmunized anti-D donorS E Dohmen, O J H M Verhagen, S M de Groot, et al.
Genome Research|April 20, 2005
Analysis of long-lived C. elegans daf-2 mutants using serial analysis of gene expressionJulius Halaschek-Wiener, Jaswinder S Khattra, Sheldon McKay, et al.
American Journal of Human Genetics|March 15, 2002
FOXP2 is not a major susceptibility gene for autism or specific language impairmentD F Newbury, E Bonora, J A Lamb, et al.
Journal of Medicinal Chemistry|April 18, 2022
Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based OptimizationKevin B Teuscher, Kenneth M Meyers, Qiangqiang Wei, et al.
Journal of Medicinal Chemistry|July 3, 2025
Antitumor Efficacy of 1,2,4-Triazole-Based VCP/p97 Allosteric InhibitorsNeal Green, Matthew G LaPorte, William Paquette, et al.
Journal of Medicinal Chemistry|December 12, 2023
Structure-Based Discovery of Potent, Orally Bioavailable Benzoxazepinone-Based WD Repeat Domain 5 InhibitorsKevin B Teuscher, Jonathan J Mills, Jianhua Tian, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 21, 2024
Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignanciesChristian T Meyer, Brianna N Smith, Jing Wang, et al.
Molecular Cancer Therapeutics|July 25, 2022
Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing DogsAmy K LeBlanc, Christina N Mazcko, Timothy M Fan, et al.
ACS Medicinal Chemistry Letters|July 19, 2023
Optimization of 1,2,4-Triazole-Based p97 Inhibitors for the Treatment of CancerMatthew G LaPorte, Celeste Alverez, Alexander Chatterley, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 27, 2022
Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal modelsKevin B Teuscher, Somenath Chowdhury, Kenneth M Meyers, et al.
Pageof 9

Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Clinical and Experimental Immunology|April 26, 2006
The analysis and quantification of a clonal B cell response in a hyperimmunized anti-D donorS E Dohmen, O J H M Verhagen, S M de Groot, et al.
Genome Research|April 20, 2005
Analysis of long-lived C. elegans daf-2 mutants using serial analysis of gene expressionJulius Halaschek-Wiener, Jaswinder S Khattra, Sheldon McKay, et al.
American Journal of Human Genetics|March 15, 2002
FOXP2 is not a major susceptibility gene for autism or specific language impairmentD F Newbury, E Bonora, J A Lamb, et al.
Journal of Medicinal Chemistry|April 18, 2022
Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based OptimizationKevin B Teuscher, Kenneth M Meyers, Qiangqiang Wei, et al.
Journal of Medicinal Chemistry|July 3, 2025
Antitumor Efficacy of 1,2,4-Triazole-Based VCP/p97 Allosteric InhibitorsNeal Green, Matthew G LaPorte, William Paquette, et al.
Journal of Medicinal Chemistry|December 12, 2023
Structure-Based Discovery of Potent, Orally Bioavailable Benzoxazepinone-Based WD Repeat Domain 5 InhibitorsKevin B Teuscher, Jonathan J Mills, Jianhua Tian, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 21, 2024
Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignanciesChristian T Meyer, Brianna N Smith, Jing Wang, et al.
Molecular Cancer Therapeutics|July 25, 2022
Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing DogsAmy K LeBlanc, Christina N Mazcko, Timothy M Fan, et al.
ACS Medicinal Chemistry Letters|July 19, 2023
Optimization of 1,2,4-Triazole-Based p97 Inhibitors for the Treatment of CancerMatthew G LaPorte, Celeste Alverez, Alexander Chatterley, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 27, 2022
Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal modelsKevin B Teuscher, Somenath Chowdhury, Kenneth M Meyers, et al.
Pageof 9